Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

5BOU

Yeast 20S proteasome in complex with a beta1 / beta2 specific non-peptidic sulfonamide Ligand

Summary for 5BOU
Entry DOI10.2210/pdb5bou/pdb
Related1RYP
DescriptorProteasome subunit alpha type-2, Proteasome subunit beta type-4, Proteasome subunit beta type-5, ... (18 entities in total)
Functional Keywordshydrolase-hydrolase inhibitor complex, proteasome, non-covalent ligand, binding analysis, hydrolase/hydrolase inhibitor
Biological sourceSaccharomyces cerevisiae S288c (Baker's yeast)
More
Cellular locationCytoplasm: P23639 P22141 P30656 P23724 P30657 P38624 P23638 P40303 P32379 P40302 P21242 P21243 P25043 P25451
Total number of polymer chains28
Total formula weight732295.20
Authors
Beck, P.,Groll, M. (deposition date: 2015-05-27, release date: 2015-08-19, Last modification date: 2024-01-10)
Primary citationBeck, P.,Reboud-Ravaux, M.,Groll, M.
Identification of a beta 1/ beta 2-Specific Sulfonamide Proteasome Ligand by Crystallographic Screening.
Angew.Chem.Int.Ed.Engl., 54:11275-11278, 2015
Cited by
PubMed Abstract: The proteasome represents a validated drug target for the treatment of cancer, however, new types of inhibitors are required to tackle the development of resistant tumors. Current fluorescence-based screening methods suffer from low sensitivity and are limited to the detection of ligands with conventional binding profiles. In response to these drawbacks, a crystallographic screening procedure for the discovery of agents with a novel mode of action was utilized. The optimized workflow was applied to the screening of a focused set of compounds, resulting in the discovery of a β1/β2-specific sulfonamide derivative that noncovalently binds between subunits β1 and β2. The binding pocket displays significant differences in size and polarity between the immuno- and constitutive proteasome. The identified ligand thus provides valuable insights for the future structure-based design of subtype-specific proteasome inhibitors.
PubMed: 26242779
DOI: 10.1002/anie.201505054
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.6 Å)
Structure validation

237423

PDB entries from 2025-06-11

PDB statisticsPDBj update infoContact PDBjnumon